Comparison tool

KLOW Blend vs Glow Protocol side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

KLOW BlendGlow Protocol

Share this peptide comparison

Property	KLOW Blend	Glow Protocol
Category	Peptide Blend	Peptide Blend
Also known as	KLOW Stack, KLOW Protocol, Advanced Healing Blend	Glow Stack, Glow Blend, Skin Rejuvenation Stack
FDA approved	No	No
Clinical status	Preclinical Research (Components) Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical Research (Components) Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Gut health, healing, anti-aging, inflammation	Skin rejuvenation, anti-aging, collagen production
How it works	The source describes four component-level rationales, not a validated action of the mixture. It characterizes GHK-Cu as a copper tripeptide studied in skin matrix contexts, while BPC-157 and TB-500 are linked to proposed angiogenesis and cell-migration effects in rodent research. According to the source, KPV is lysine-proline-valine from alpha-MSH's carboxyl terminus; cell and intestinal work is described as involving NF-kB inhibition and PepT1-mediated uptake, respectively. These findings do not establish effects for KLOW Blend or for injectable use.	Glow Protocol is described as a three-component peptide blend. GHK-Cu is the copper-binding tripeptide in the stack and is linked in the source to collagen, elastin, glycosaminoglycan production, matrix metalloproteinase modulation, and angiogenesis signals from cell and animal evidence. BPC-157 is included for proposed pro-healing and anti-inflammatory activity tied to angiogenesis and growth-factor signaling in rodent studies. TB-500 is described as an actin-binding thymosin beta-4 fragment included for cell migration and tissue-remodeling hypotheses. The source explicitly frames the combined mechanism as plausible extrapolation rather than proof that the injectable blend works as a unified product.
Typical dosing	Standard vial dosing per protocol · Once daily	Standard vial dosing per protocol · Once daily
Research dosing	GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg · 8-12 weeks · Subcutaneous injection	5:1:1 ratio GHK-Cu:TB-500:BPC-157 · 8-12 weeks for visible results · Subcutaneous injection
Typical duration	8-12 weeks	8-12 weeks for visible results
Administration	Subcutaneous injection	Subcutaneous injection
Timing	Morning or evening With or without food	Evening With or without food
Evidence level	Preclinical	Preclinical
Possible side effects	Injection site reactions (Reported by the supplied source; no frequency or severity detail was provided.) Mild fatigue initially (Reported by the supplied source as mild and occurring initially.) Temporary GI changes (as gut heals) (The supplied source labels these changes temporary and associates them with gut healing; that association is not independently established.) +1 more Headache (rare) (Reported by the supplied source as rare.)	Injection site reactions Temporary skin flushing Mild headache (Reported as rare in the source.) +1 more Fatigue during initial use
Research summary	The supplied source reports no human trial of the KLOW combination. It further states that BPC-157, TB-500, and KPV lack completed human efficacy trials, whereas the human support it attributes to GHK-Cu is limited to topical skincare rather than this blend. For KPV, the source describes oral mouse studies of chemically induced colitis using DSS and TNBS, with reduced disease severity alongside proposed PepT1 uptake and NF-kB-related mechanisms. Taken together, these are separate component findings and do not validate the combined injectable formulation.	The source distinguishes the evidence for the ingredients. GHK-Cu is described as having the strongest human support, but specifically from topical cosmetic studies rather than injectable Glow Protocol use; reported topical outcomes include reduced wrinkle depth and better skin density and firmness across 8 to 12 weeks. A gene-profiling analysis is also cited as finding broad GHK associations with wound-repair and inflammation-related human genes, but the source characterizes that as computational rather than direct clinical evidence. BPC-157 and TB-500 are described as remaining in the animal-data category without completed human efficacy trials. The source further states that the injected GLOW blend has no published trial of its own, so topical GHK-Cu results should not be assumed to apply to the injectable three-peptide blend. It also flags injection of copper peptides as a risk area not addressed by topical studies.
References	Source Source +2 more Source Source	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

KLOW Blend

Glow Protocol

Category

Peptide Blend

Also known as

KLOW Stack, KLOW Protocol, Advanced Healing Blend

Glow Stack, Glow Blend, Skin Rejuvenation Stack

FDA approved

Clinical status

Preclinical Research (Components)

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical Research (Components)

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Gut health, healing, anti-aging, inflammation

Skin rejuvenation, anti-aging, collagen production

How it works

The source describes four component-level rationales, not a validated action of the mixture. It characterizes GHK-Cu as a copper tripeptide studied in skin matrix contexts, while BPC-157 and TB-500 are linked to proposed angiogenesis and cell-migration effects in rodent research. According to the source, KPV is lysine-proline-valine from alpha-MSH's carboxyl terminus; cell and intestinal work is described as involving NF-kB inhibition and PepT1-mediated uptake, respectively. These findings do not establish effects for KLOW Blend or for injectable use.

Glow Protocol is described as a three-component peptide blend. GHK-Cu is the copper-binding tripeptide in the stack and is linked in the source to collagen, elastin, glycosaminoglycan production, matrix metalloproteinase modulation, and angiogenesis signals from cell and animal evidence. BPC-157 is included for proposed pro-healing and anti-inflammatory activity tied to angiogenesis and growth-factor signaling in rodent studies. TB-500 is described as an actin-binding thymosin beta-4 fragment included for cell migration and tissue-remodeling hypotheses. The source explicitly frames the combined mechanism as plausible extrapolation rather than proof that the injectable blend works as a unified product.

Typical dosing

Standard vial dosing per protocol · Once daily

Research dosing

GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg · 8-12 weeks · Subcutaneous injection

5:1:1 ratio GHK-Cu:TB-500:BPC-157 · 8-12 weeks for visible results · Subcutaneous injection

Typical duration

8-12 weeks

8-12 weeks for visible results

Administration

Subcutaneous injection

Timing

Morning or evening

With or without food

Evening

With or without food

Evidence level

Preclinical

Possible side effects

Injection site reactions (Reported by the supplied source; no frequency or severity detail was provided.)
Mild fatigue initially (Reported by the supplied source as mild and occurring initially.)
Temporary GI changes (as gut heals) (The supplied source labels these changes temporary and associates them with gut healing; that association is not independently established.)

+1 more

Headache (rare) (Reported by the supplied source as rare.)

Injection site reactions
Temporary skin flushing
Mild headache (Reported as rare in the source.)

+1 more

Fatigue during initial use

Research summary

The supplied source reports no human trial of the KLOW combination. It further states that BPC-157, TB-500, and KPV lack completed human efficacy trials, whereas the human support it attributes to GHK-Cu is limited to topical skincare rather than this blend. For KPV, the source describes oral mouse studies of chemically induced colitis using DSS and TNBS, with reduced disease severity alongside proposed PepT1 uptake and NF-kB-related mechanisms. Taken together, these are separate component findings and do not validate the combined injectable formulation.

The source distinguishes the evidence for the ingredients. GHK-Cu is described as having the strongest human support, but specifically from topical cosmetic studies rather than injectable Glow Protocol use; reported topical outcomes include reduced wrinkle depth and better skin density and firmness across 8 to 12 weeks. A gene-profiling analysis is also cited as finding broad GHK associations with wound-repair and inflammation-related human genes, but the source characterizes that as computational rather than direct clinical evidence. BPC-157 and TB-500 are described as remaining in the animal-data category without completed human efficacy trials. The source further states that the injected GLOW blend has no published trial of its own, so topical GHK-Cu results should not be assumed to apply to the injectable three-peptide blend. It also flags injection of copper peptides as a risk area not addressed by topical studies.

References

+2 more

+2 more

Full profile